Redhawk Wealth Advisors Inc. Buys Shares of 47,497 Pfizer Inc. $PFE

Key Points

• Redhawk Wealth Advisors Inc. acquired a new stake in Pfizer Inc., purchasing 47,497 shares valued at approximately $1.15 million during the 2nd quarter.
• Analysts' price targets for Pfizer's stock show a range, with Bank of America setting a target of $28.00, while Berenberg Bank lowered its target to $25.00.
• Pfizer recently announced a quarterly dividend of $0.43 per share, representing an annualized yield of 7.1% and a payout ratio of 91.49%.

Redhawk Wealth Advisors Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 47,497 shares of the biopharmaceutical company's stock, valued at approximately $1,151,000.

A number of other institutional investors have also recently bought and sold shares of PFE. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $27,000. North Capital Inc. bought a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer in the 4th quarter worth about $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Bank of America raised their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

PFE stock traded up $0.27 during trading on Monday, hitting $24.30. 39,730,680 shares of the company's stock traded hands, compared to its average volume of 45,230,422. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The business has a fifty day simple moving average of $24.63 and a 200 day simple moving average of $24.20. The stock has a market capitalization of $138.13 billion, a price-to-earnings ratio of 12.93, a P/E/G ratio of 0.78 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the business earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.